266
Views
5
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma

, , &
Pages 1581-1588 | Received 23 Jan 2016, Accepted 18 Oct 2016, Published online: 10 Nov 2016
 

Abstract

The aim of this study was to discuss 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma (AITL). The PET/CT features of 24 cases of pathologically confirmed AITL were analyzed. The individual and total diagnostic values of 13 sites using computed tomography (CT) and positron emission tomography (PET)/CT were calculated. The maximum standard uptake value (SUVmax) of lesions with lymph node infiltration and extranodal organ infiltration were 5.4–25.1 (median, 9.7) and 1.5–12.5 (median, 5.5), respectively. The diagnostic sensitivity, specificity and accuracy of AITL using CT were 78.3%, 100%, and 87.8%, respectively; using PET/CT, these values were 98.9%, 100%, and 99.4%, respectively. One patient undergoing PET/CT staging was upstaged from stage II to III, and two patients were upstaged from stage III to IV. PET/CT is very valuable in the diagnosis and staging of AITL.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1253834.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.